HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.

AuthorsGiuseppe G Loscocco, Elisabetta Antonioli, Ilaria Romano, Federica Vergoni, Giada Rotunno, Francesco Mannelli, Paola Guglielmelli, Alessandro M Vannucchi
JournalAmerican journal of hematology (Am J Hematol) Vol. 96 Issue 6 Pg. 749-754 (06 01 2021) ISSN: 1096-8652 [Electronic] United States
PMID33719069 (Publication Type: Case Reports, Journal Article)
Chemical References
  • CALR protein, human
  • Calreticulin
  • Dexamethasone
  • Lenalidomide
  • Aspirin
  • Hydroxyurea
Topics
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Aspirin (therapeutic use)
  • Bone Marrow (pathology)
  • Calreticulin (genetics)
  • Dexamethasone (administration & dosage)
  • Humans
  • Hydroxyurea (adverse effects, therapeutic use)
  • Lenalidomide (administration & dosage)
  • Male
  • Monoclonal Gammopathy of Undetermined Significance (complications, diagnosis, pathology)
  • Multiple Myeloma (complications, diagnosis, drug therapy)
  • Osteolysis (etiology)
  • Primary Myelofibrosis (diagnosis, drug therapy, etiology)
  • Remission Induction
  • Risk Factors
  • Sequence Deletion
  • Stomatitis, Aphthous (chemically induced)
  • Thrombocythemia, Essential (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: